Background: To assess the prognostic role of human epidermal growth factor receptor 2 (HER2) overexpression in patients with ductal carcinoma in situ (DCIS).
Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ Results: We identified 560 (33.5%) patients with HER2-positive DCIS. The median follow-up was 7.6 years (interquartile range 5.9-9.5). We observed 422 events out of 1667 patients, with 141 in situ recurrences, 201 invasive recurrences and 80 other events (64 second primaries and 16 deaths). The 10-year isBCR proportions were 11.8% [95% confidence interval (CI) 9.0% to 15 .4%] in the HER2-positive group and 8.8% (95% CI 6.9% to 11.0%) in the HER2-negative group (Gray test, P = 0.010). At multivariable analysis, the adjusted risk of isBCR was higher in the HER2-positive group than in the HER2-negative group [hazard ratio (HR) HER2 positive versus negative: 1.59 (95% CI 1.06-2.39)]. We observed significant differences both in BCR and isBCR for patients treated by quadrantectomy without radiotherapy versus patients treated with radiotherapy [adjusted HR HER2 positive versus negative: 1.53 (95% CI 1.07-2.18) and adjusted HR HER2 positive versus negative: 2.18 (95% CI 2.18-3.69), respectively].
Conclusion: HER2 overexpression predicts an increased risk of isBCR. Radiotherapy reduces local failure rates in HER2-positive DCIS. Key words: ductal carcinoma in situ, epidermal growth factor receptor 2 (HER2) overexpression introduction Ductal carcinoma in situ (DCIS) has become a relatively common disease after the introduction of screening mammography, representing up to 20%-25% of all breast malignancies in industrialized countries [1, 2] . DCIS is defined as a malignant proliferation of ductal cells of the breast that does not invade through the basal membrane. Conventional local management of DCIS includes surgical resection by either mastectomy or breast-conserving surgery and radiation therapy [2] [3] [4] . Patients with hormone receptor-positive tumors benefit from adjuvant treatment with tamoxifen that decreases local and contralateral recurrence [5] . Despite its excellent prognosis, DCIS may recur in up to 10% of patients, and almost 50% of the recurrences are invasive [6] . HER2 overexpression is a common feature of DCIS. While 15%-20% of invasive breast cancers are HER2-positive, overexpression and amplification of this gene is as high as 60%-70% in patients with high-grade/comedo DCIS [7] [8] [9] . Overexpression of HER2 is associated with high histological grade, occurrence of comedo-necrosis and p53 mutation, and it is inversely associated with the expression of hormone receptors [10, 11] . HER2 is a validated therapeutic target in invasive breast cancer, leading to the hypothesis that its inhibition through anti-HER2 therapy could also be beneficial for patients with DCIS [12, 13] . In order to assess if HER2 overexpression in DCIS lesions is associated with a higher risk of invasive cancer or recurrent DCIS, we interrogated a large retrospective single-center series of women with HER2-positive DCIS treated by multimodal approach, to determine the risk of subsequent disease as a function of HER2 overexpression.
patients and methods

study population
We carried out a retrospective analysis through the institutional clinical database on all consecutive women with de novo DCIS who underwent surgery at the European Institute of Oncology, Milan, Italy, between January 1996 and December 2008. Data on patients' medical history, concurrent diseases, type of surgery, pathological assessment of morphological and biological features were combined. DCIS were classified according to ductal intraepithelial neoplasia (DIN) classification as follows: DIN 1c: DCIS grade 1 (low grade); DIN2: DCIS grade 2 (intermediate grade); DIN3: DCIS grade 3 (high grade) [14, 15] . Estrogen receptor (ER), progesterone receptor (PgR) status and Ki-67 labeling index were determined as previously reported [6] . HER2 immunohistochemical (IHC) expression was evaluated using the A0485 polyclonal antiserum and, since 2007, the HercepTest (both from Dako, Glostrup, Denmark). HER2 IHC expression was scored as follows: 0 (any staining in <10% of the neoplastic cells), 1+ (faint incomplete membrane staining in >10% of tumor cells), 2+ (weak-to-moderate complete membrane staining in >10% of tumor cells) and 3+ (intense complete membrane staining in >10% of tumor cells). Biomarker assessment was retrospectively collected. ER and PgR were scored positive if finding of ≥1% of tumor cell nuclei immunoreactive. Ki-67 cutoff was defined ad ≥14% of stained cells.
Clinical and pathological data were entered by surgeons into a 'user-friendly' database®. Data were available regarding age, menopausal status, date of surgery, tumor characteristics (tumor size, grade, Ki-67, ER/PgR and HER2 expression, necrosis, microcalcifications and multifocality) and treatment modality (type of surgery, adjuvant radiotherapy and/or endocrine therapy).
We identified female patients with a de novo DCIS with the following characteristics: M0, pN0, pTis and HER2/neu protein overexpression (study group). The data collection was approved by the Institutional Review Board.
statistical methods
Differences in the distribution of subject characteristics between groups were evaluated by the χ 2 test. The end points evaluated were cumulative incidence of In-Situ Breast cancer Recurrence (isBCR), INvasive Breast Cancer Recurrence (IBCR) and any Breast Cancer recurrence (BCR). isBCR, IBCR and BCR were defined as the time from surgery to the breast cancer recurrence as first event (in situ, invasive or both, respectively) or to last visit in case of no events. Other first events such as other primary tumors and deaths were considered as competing events. The isBCR, IBCR and BCR functions were estimated according to methods described by Kalbfleisch and Prentice [16] , taking into account the competing causes of recurrence. The Gray's test was used to assess cumulative incidence differences between groups. The hazard ratios (HRs) comparing patients with HER2-positive tumor versus patients with HER2-negative tumor were estimated with a Cox proportional hazards multivariable model, controlled for ER/PgR expression, hormone therapy, type of surgery, radiotherapy, menopausal status and tumor grade. All analyses were carried out with the SAS software (SAS Institute, Cary, NC) and the R software (http:// cran.r-project.org/) with the cmprsk package developed by Gray (http:// biowww.dfci.harvard.edu/~gray/). All reported P values are two-sided.
results
From January 1996 to December 2008, a total of 1667 patients with DCIS grade 1-3 were referred to the interdisciplinary evaluation. Among this population, we identified a total of 560 cases with HER2 overexpression (3+). Table 1 . Nearly 50% (n = 277) of HER2-positive DCIS were ER and PgR negative, almost 90% (n = 501) had Ki-67 ≥14% and 60% (n = 336) were G3. The median follow-up was 7.6 years (interquartile range 5.9-9.5).
We observed 422 first events among the 1667 patients: 141 (8.5%) in situ recurrences, 201 (12.1%) invasive recurrence and 80 other events (64 s primaries and 16 deaths). We included in isBCR, IBCR and BCR events also controlateral tumors (both in situ and infiltrating). BCR includes isBCR and IBCR (Table 2) . A significant difference was observed in isBCR when comparing HER2-positive and -negative groups. The 10-year isBCR proportions were 11.8% (n = 61 of 560) (95% CI 9.0% to 15.4%) in the HER2-positive group and 8.8% (n = 80 of 1107) (95% CI 6.9% to 11.0%) in the HER2-negative group (Gray test, P = 0.010). At multivariable analyses, the adjusted risk of isBCR was higher in the HER2-positive group than in the HER2-negative group [HR HER2 positive versus negative: 1.59 (95% CI 1.06-2.39) as shown in Figure 1 ] . We carried out a multivariate analysis stratifying the association between events of interest and size, margins and age, and we did not found a statistically significant association in BCR or IBCR. The 10-year BCR proportions were 23.8% (n = 120) (95% CI 19.7% to 28.7%) in the HER2-positive group and 24.6% (n = 222) (95% CI 21.5% to 28.1%) in the HER2-negative group, (Gray test, P = 0.44). The 10-year IBCR proportions were 12% (n = 59) (95% CI 9.0% to 16.1%) in the HER2-positive group and 15.8% (n = 142) (95% CI 13.3% to 18.8%) in the HER2-negative group (Gray test, P = 0.18).
The The subgroup analysis by local treatment (surgery and radiotherapy) showed a significant difference in BCR and isBCR for patients treated by quadrantectomy without radiotherapy (n = 54) versus patients treated with radiotherapy (n = 48) [adjusted HR HER2 positive versus negative: 1.53 (95% CI 1.07-2.18) and adjusted HR HER2 positive versus negative: 2.18 (95% CI 2.18-3.69), respectively] whereas no significant difference was observed in IBCR [adjusted HR HER2 positive versus negative: 1.14 (95% CI 0.69-1.88)] (supplementary Figure S3 , available at Annals of Oncology online). No significant difference was observed in BCR, isBCR and IBCR in patients that underwent quadrantectomy and received radiotherapy or in patients that underwent mastectomy (supplementary Figure S3, Figure S4 , available at Annals of Oncology online). Supplementary Figure S5 , available at Annals of Oncology online, summarized as a flow chart of all the cohort of patients included in the analysis and events described.
discussion
We assessed the prognostic value of HER2 overexpression in women with DCIS to quantify the risk of subsequent DCIS or invasive cancer. Our findings corroborate previous results of population-based cohort studies of individuals with DCIS treated by breast-conserving surgery [8, [17] [18] [19] . In our study, HER2 overexpression in primary DCIS was associated with a higher risk of in situ recurrence. Notably, no association with a higher risk of IBCR was noted. We described the prognostic significance of Ki-67 status as predictive marker in DCIS [6] . In this analysis, Ki-67 appeared to be a useful prognostic and predictive biomarker in DCIS patients for better selection of adjuvant treatment. The role of HER2 in DCIS is unclear. It has been proposed that HER2 overexpression in DCIS is of major importance for tumor progression toward invasive cancer [18, 20, 21] . The findings from our present study cannot confirm such an influence regarding progression to invasive tumor. Recently, Agosto-Arroyo et al have shown that some HER2-positive DCIS are associated with high risk of developing invasive breast cancer, when compared with more indolent DCIS [22] . They carried out gene expression profiles in high nuclear grade DCIS. Approximately 30 genes were identified to be expressed differently in the HER2 subtype when compared with the two other groups (ER/PR+ and triple negative). Uncovering gene expression signatures of HER2-positive DCIS can enhance our understanding of the mechanisms of breast cancer progression and become the basis for developing new predictive biomarkers and/or therapeutic targets. The subgroup analysis by local treatment (surgery and radiotherapy) showed significant differences both in BCR and isBCR for patients treated by quadrantectomy without radiotherapy [adjusted HR HER2 positive versus negative: A number of studies aimed at identifying factors that predict the risk of invasive recurrence following a diagnosis of DCIS, but few have included HER2 in their analyses. Our series is, to our knowledge, the largest ever published with HER2 assessed. HER2 status is not routinely assessed in clinical practice and there is no indication to anti-HER2 blockade in the preventive setting. Preclinical reports associated HER2 signaling with tumor cell migration, expression of proangiogenic factors and cyclooxygenase-2, suggesting a potentially significant role in inducing invasion or the elaboration of a stroma that supports tumor growth [25, 26] . The close association between HER2-overexpressing phenotypes and increased risk of isBCR should have clinical implications. First, indication to radiotherapy should be mandatory to ER/PgR-negative, HER2-positive DCIS in addition to the presence of necrosis and/or high tumor grade. Secondly, patients with HER2-positive DCIS could benefit from magnetic resonance imaging (MRI) surveillance program. In a prospective observational study comparing MRI to mammography, MRI was more sensitive and specific in diagnosing high-grade DCIS; in this report, 48% of DCIS were missed by mammography, but diagnosed by MRI alone [27] . Third, the fundamental question now, having documented a major risk of local recurrence, is what to do next in terms of systemic therapy. A trial with trastuzumab in HER2-positive DCIS was conducted [28] . In that study, a single loading dose of 8 mg/kg of trastuzumab was administered to test the biological effects of the agent on DCIS 3-4 weeks before surgical resection. Twelve patients received study drug and 12 patients served as controls with no treatment. Pre-and post-treatment tissues with DCIS were studied for proliferation and apoptosis in patients treated with trastuzumab. The conclusion was that a single-dose monotherapy with trastuzumab for patients with HER2-positive DCIS does not result in significant clinically, histologic, proliferative or apoptotic changes but results in an antibody-dependent cellmediated cytotoxicity response through NK cells and may also induce humoral immunity in a T-cell-dependent manner [28] . A second study was conducted in our institution [29] . It was a randomized, placebo-controlled trial of lapatinib (1500 mg/day) administered orally for 3 weeks between biopsy and surgery in 60 women with HER-2-positive breast cancer to assess lapatinib biomarker (including the primary end point, Ki-67) and clinical activity in invasive breast cancer, adjacent ductal intraepithelial neoplasia (which comprises DCIS and atypical ductal hyperplasia), and distant ductal hyperplasia (DH) without atypia. In our study, short-term lapatinib significantly decreased cell proliferation in DIN, DH and invasive HER-2-positive (especially ER-negative) breast cancer [29] . In a third study, patients with HER2-positive DCIS received 1500 mg daily of lapatinib for 4 consecutive weeks before surgical resection [30] . MRI was used to determine changes in tumor volume. The molecular effects of lapatinib on HER2 signaling (PI3K/AKT and RAS/MAPK pathways), cell proliferation (Ki-67 and p27) and apoptosis (TUNEL) were determined in pre-and post-lapatinib treatment samples. A total of 20 patients were included. Lapatinib was well tolerated with only minor and transient side-effects. The agent effectively modulated HER2 signaling decreasing significantly pHER2 and pERK1 expression, together with a decrease in tumor size evaluated by MRI. There was no evidence of changes in Ki-67 [30] . To determine the clinical effect of anti-HER2 blockade, the National Surgical Adjuvant Breast Project (NSABP) B-43 phase III randomized trial is currently ongoing to test the efficacy of adding trastuzumab to conventional surgical and radiation therapy treatment of patients with HER2-overexpressing DCIS.
Our study does not support the premise that HER2 overexpression in primary DCIS is of any major importance for tumor progression toward invasive cancer which has been proposed. However, more studies are needed to evaluate the impact of other biomarkers that differentiate individuals at risk of in situ recurrence from those at risk of developing invasive one. The evaluation of joint expression of HER2/neu, Ki-67 and of other combinations of biomarkers on the risks of local and invasive recurrence could help clinicians in the addressing
